The PBAC has recommended the PBS listing of the infliximab biosimilar Inflectra™ for the same indications that apply to its comparator drug Remicade™. It has also recommended Inflectra™ for ‘a’ flagging, meaning pharmacists can substitute biosimilars for brand name original biologics. However as reported by the limbic last month the ‘a’ flagging of biosimilars has ...
Infliximab biosimilar recommended for PBS
By Nicola Garrett
24 Aug 2015